In Nasopharyngeal Carcinoma Cells, Epstein-Barr Virus LMP1 Interacts with Galectin 9 in Membrane Raft Elements Resistant to Simvastatin

Catherine Pioche-Durieu,1† Cécile Keryer,1† Sylvie Souquère,2 Jacques Bosq,3 Wolfgang Faigle,4 Damarys Loew,4 Mitsuomi Hirashima,5 Nozomu Nishi,6 Jaap Middeldorp,7 and Pierre Busson1*

UMR 8126 CNRS, Institut Gustave Roussy, Villejuif, France; CNRS UPR 1983, Institut André Lwoff, Villejuif, France; Département d’Anatomie Pathologique, Institut Gustave Roussy, Villejuif, France; Laboratoire de Spectrométrie de Masse, Institut Curie, 75005 Paris, France; Department of Immunopathology, Faculty of Medicine, Kagawa University, Japan; Department of Endocrinology, Faculty of Medicine, Kagawa University, Japan; and Department of Pathology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Received 1 May 2005/Accepted 22 July 2005

Nasopharyngeal carcinomas (NPC) are etiologically related to the Epstein-Barr virus (EBV), and malignant NPC cells have consistent although heterogeneous expression of the EBV latent membrane protein 1 (LMP1). LMP1 trafficking and signaling require its incorporation into membrane rafts. Conversely, raft environment is likely to modulate LMP1 activity. In order to investigate NPC-specific raft partners of LMP1, rafts derived from the C15 NPC xenograft were submitted to preparative immunoprecipitation of LMP1 combined with mass spectrometry analysis of coimmunoprecipitated proteins. Through this procedure, galectin 9, a beta-galactoside binding lectin and Hodgkin tumor antigen, was identified as a novel LMP1 partner. LMP1 interaction with galectin 9 was confirmed by coimmunoprecipitation and Western blotting in whole-cell extracts of NPC and EBV-transformed B cells (lymphoblastoid cell lines [LCLs]). Using mutant proteins expressed in HeLa cells, LMP1 was shown to bind galectin 9 in a TRAF3-independent manner. Galectin 9 is abundant in NPC biopsies as well as in LCLs, whereas it is absent in Burkitt lymphoma cells. In subsequent experiments, NPC cells were treated with Simvastatin, a drug reported to dissociate LMP1 from membrane rafts in EBV-transformed B cells. We found no significant effects of Simvastatin on the distribution of LMP1 and galectin 9 in NPC cell rafts. However, Simvastatin was highly cytotoxic for NPC cells, regardless of the presence or absence of LMP1. This suggests that Simvastatin is a potentially useful agent for the treatment of NPCs although it has distinct mechanisms of action in NPC and LCL cells.

Nasopharyngeal carcinoma (NPC) is one of the best examples of a human solid tumor which is consistently associated with a virus (7). NPC is rare in Europe and North America (<3 cases/100,000 persons/year), but it remains a major public health problem in several areas of Asia and Africa. Very-high-incidence foci are found in south China, especially in Guangdong and Guangxi provinces (25 to 40 cases per 100,000 persons/year) and also in other populations of southeast Asia, for example, in the Sarawak people of Borneo island (14). Intermediate risk areas include the Philippines, Vietnam, Indonesia, and several countries of North and West Africa (incidence of 4 to 8 cases/100,000 persons/year). Most NPCs have minimal epithelial maturation and are classified as undifferentiated (World Health Organization [WHO] type III) or poorly differentiated (WHO type II). A few cases are differentiated (WHO type I). Epstein-Barr virus (EBV) association is constant regardless of patient origin and tumor differentiation except for some very rare cases of differentiated NPC (type I) in western countries (47). Another striking constant feature of NPC is the presence of a massive lymphoid infiltrate in the primary tumor. This infiltrate contains mostly T lymphocytes and a minority of B cells, monocytes, eosinophils, and dendritic cells. It results at least in part from a massive production of inflammatory cytokines by malignant cells, including interleukin 1α, interleukin 1β and macrophage inhibitory protein 1 (6, 26, 57).

EBV infection in NPC cells is mainly latent. Several copies of the EBV genome (about 170 kb) are contained in the nuclei of malignant cells, generally in the form of circular independent DNA molecules called episomes. Most of the about 80 EBV genes are silent in NPC cells, but some of them are consistently expressed (50). Two of these genes encode small untranslated EBV-encoded RNAs (28). Other EBV genes consistently transcribed in NPC encode viral proteins with proven or suspected oncogenic properties like Epstein-Barr nuclear antigen 1 (EBNA1), latent membrane protein 1 (LMP1) and LMP2, and the BARF1 protein (5, 23, 55). Currently, only EBNA1 and LMP1 are detected in NPC cells by routine immunohistochemistry (detection of LMP2 requires special techniques to enhance antibody staining) (23). EBNA1 is a chromatin-associated protein that is involved in EBV genome
LMP1 in these structures. Kaykas et al. have not been able to identify additional cellular partners of association of LMP1 with these subcellular elements. Al-

carrying LMP1 has remained elusive since we first reported the and flotation on a density gradient. Most authors simply iden-

tifying complexes through a procedure of cell fractionation and receptor-associated death domain (TRADD) protein, and the gp85 subunit of the phosphatidylinositol 3-kinase. The C-terminal intracytoplasmic domain can bind a series of cellular signaling adaptors including TRAF3, tumor necrosis factor receptor-associated death domain (TRADD) protein, and poly(ADP-ribose) polymerase-associated death domain (TRADD) protein, and its incorporation into membrane rafts (19, 27, 39, 45, 66). In EBV-transformed B cells, LMP1 signaling pathways are adjusted in order to draw cells through the G1/S checkpoint and simultaneously prevent apoptosis in a majority of cells. There is a consensus that three types of molecular processes are required for optimal activation of most LMP1 signaling pathways: its own oligomerization; the capture of its intracellular portion of LMP1; its target epitopes map in the variable 11 amino acid repeats between residues 205 to 308 and close to residue 386 at the very C terminus of LMP1; its target epitopes map in the variable 11 amino acid repeats of LMP1. OT21C was affinity purified over the 11 amino acid repeats of LMP1 (44). It was also affinity purified prior to its use in this study. Galectin 9 was detected using an affinity-purified polyclonal anti-

Materials and Methods

Tumor and cell lines. C15 and C17 are EBV-positive NPC tumor lines per-

mance of cell fractionation and flotation on a density gradient. Most authors simply iden-

tifying complexes through a procedure of cell fractionation and receptor-associated death domain (TRADD) protein, and its incorporation into membrane rafts (19, 27, 39, 45, 66). In EBV-transformed B cells, LMP1 signaling pathways are adjusted in order to draw cells through the G1/S checkpoint and simultaneously prevent apoptosis in a majority of cells. There is a consensus that three types of molecular processes are required for optimal activation of most LMP1 signaling pathways: its own oligomerization; the capture of its intracellular portion of LMP1; its target epitopes map in the variable 11 amino acid repeats between residues 205 to 308 and close to residue 386 at the very C terminus of LMP1; its target epitopes map in the variable 11 amino acid repeats of LMP1. OT21C was affinity purified over the 11 amino acid repeats of LMP1 (44). It was also affinity purified prior to its use in this study. Galectin 9 was detected using an affinity-purified polyclonal anti-

Antibodies. LMP1 was detected using three types of reagents. CS1-4 (Dako- 

cytometry, Denmark) is a pool of four monoclonal antibodies directed to the C terminus of LMP1; its target epitopes map in the variable 11 amino acid repeats between residues 205 to 308 and close to residue 386 at the very C terminus (44, 52). CS1-4 was used under the form of hybridoma culture supernatant, as provided by the manufacturer. OT21C is a monoclonal antibody that reacts with a conformational epitope mapping at residues 290 to 318, thus overlapping the 11 amino acid repeats of LMP1 (44). OT21C was affinity purified and used mainly for immunoprecipitation. OT22CN is a monoclonal antibody that reacts with an epitope contained in residues 1 to 23 in the amino-terminal intracytoplasmic portion of LMP1 (44). It was also affinity purified prior to its use in this study. Galectin 9 was detected using an affinity-purified polyclonal anti-

In order to progress in the characterization of these complexes, we undertake to identify novel partner proteins associated with LMP1 in membrane rafts using a direct approach based on preparative immunoprecipitation and mass spectrometry (MS) analysis. This approach was applied to NPC cells having spontaneous LMP1 expression. We report that LMP1 interacts with galectin 9, a protein previously identified in Hodgkin’s disease, which appears to be extremely abundant in NPC cells. Association of LMP1 and galectin 9 with the rafts was not inhibited by the raft-modifying agent Simvastatin, in contrast with a previous report regarding EBV-transformed B cells (31). However, Simvastatin appeared to be highly cyto-

toxic for NPC cells by an LMP1-independent mechanism.

Eukaryotic expression vectors and transfections. All transfected genes were expressed by short-term transfections, except for the previously described HL8 clone derived from HeLa cells and having stable expression of the full-length B95-8 LMP1 under the control of the metallothionein promoter (2). Short-term transfections were also done in HeLa cells using DOPAT [N-[1-(2,3-diole-

yl)propyl]-N,N,N-trimethylammonium methylsulfate] cationic liposomes (Roche Molecular, Meylan, France). Cells were harvested 24 h after transfection. The full-length galectin 9 cDNA coding the short cytoplasmic domain (residues 1 to 10) was expressed under the control of the cytomegalovirus (CMV) promoter in the pBk-CMV plasmid from Stratagene (La Jolla, CA). LMP1 cDNA from the B95-8 strain, either full-length or deleted of the PXQXT motif at codons 204 to 208, was expressed from the pcDNA3 plasmid (Invitrogen) (2).
Tumor pieces (500 mg) or cell suspensions (about 10^8 cells) were sonicated, and clarified in the same way as for tumor extracts. Cells were homogenized in a tight-fitting conical glass homogenizer and sonicated (three times for 10 s each time) on ice. Extracts were clarified by centrifugation for 15 min at 16,000 × g at 4°C. Cultured cells were simply solubilized in RIPA buffer with Complete protease inhibition mixture, sonicated, and clarified in the same way as for tumor extracts.

Isolation of rafts (rotation assay). Rafts were isolated by Triton X-100 extraction and flotation through a sucrose step gradient as previously described (Roche Molecular, Meylan, France). Tumor pieces were homogenized in a tight-fitting conical glass homogenizer and sonicated (three times for 10 s each time) on ice. Extracts were clarified by centrifugation for 15 min at 16,000 × g at 4°C. Cultured cells were simply solubilized in RIPA buffer with Complete protease inhibition mixture, sonicated, and clarified in the same way as for tumor extracts.

Preparative immunoprecipitations. Preparative immunoprecipitations were made on raft complexes prior to tandem MS (MS/MS) analysis, using 45 μg of OT21C monoclonal antibody covalently cross-linked on 4.5 μg of protein. Rafts were used for preparative or analytical immunoprecipitations. In other experiments, all fractions—initial extract, LSP, HSP, rafts, and F40—were analyzed by direct polyacrylamide gel electrophoresis (PAGE) and Western blotting. The relative concentration of proteins loaded in each lane were identical (for example, 30 μg of total proteins). Practically, slices were cut in 1- by 1-mm pieces which were washed three times by sequential immersions in 25 mM NH₄HCO₃ and plain acetonitrile and then dried. Dried gel pieces were reduced and alkylated by using dithiothreitol and iodoacetamide, respectively. Gel pieces were dried again after a new cycle of washings as described above. In-gel trypsin digestion was performed overnight at 30°C (20 ng/mL in NH₄HCO₃ solution; Sigma). Finally, protein digests were extracted by the addition to gel pieces of a mixture of acetonitrile–H₂O–HCOOH (60:35:5 [vol/vol/vol]), followed by sonication and centrifugation. Supernatants containing tryptic peptides were vacuum dried to a very small volume (1 or 2 μl) and then digested again in 5% acetonitrile (H₂O, 95%).

Protein concentration assay. In all tumor and cell extracts or fractions, protein concentration was assayed by the Lowry method using a detergent-compatible microassay system (Bio-Rad, Marnes-la-Coquette, France).

Western blotting. Western blotting was performed on polyvinylidene difluoride membranes (Immobilon P; Millipore, St. Quentin en Yvelines, France) according to the manufacturer’s instructions (Roche Molecular, Meylan, France). Protein samples were electrophoresed and transferred onto nitrocellulose membranes (Immobilon P; Millipore, St. Quentin en Yvelines, France). Membranes were blocked in 5% skim milk in PBS-T for 1 h at room temperature. In the next step, sections were incubated with the EnVision polyclonal or monoclonal antibody (DakoCytomation, Trappes, France) conjugated to peroxidase for 45 min at room temperature. After endogenous peroxidase was blocked with H₂O₂, they were incubated with the affinity-purified anti-galectin 9 rabbit antibody against galectin 9 was the same as for Western blotting, used at 5 μg/mL. Secondary anti-mouse and anti-rabbit antibodies were conjugated to Alexa 488 and Alexa 488, respectively (Molecular Probes, Invitrogen, Cergy-Pontoise, France). Observations were made with a confocal microscope (Zeiss LSM510).

Immunostaining of fresh NPC biopsies. Tissue sections were dewaxed, rehydrated, and microwaved at 98°C for 20 min in citrate buffer (10 mM, pH 7.3). After endogenous peroxidase was blocked with H₂O₂, they were incubated with the affinity-purified anti-galectin 9 rabbit antibody at 5 μg/mL for 60 min at room temperature. In the next step, sections were incubated with the EnVision polymer (DakoCytomation, Trappes, France) conjugated to peroxidase for 45 min at room temperature and subsequently with diaminobenzidine used as a chromogenic substrate of peroxidase. Finally, sections were counterstained with Mayer’s hematoxylin for 8 s, dehydrated, and mounted.

Electron microscopy. Cell pellets were fixed with 1.6% glutaraldehyde at 4°C, followed by treatment with osmium tetroxide, and then dehydrated and embedded in Epon resin. Ultrathin sections were cut on an LKB-III ultra-microtome, stained for contrast with uranyl acetate and lead citrate, and examined with a Zeiss EM 902 transmission electron microscope.
In vitro pharmacological assays on NPC cells. Prior to in vitro experiments, xenografted C15 tumors were minced and treated with type II collagenase for cell dispersion as previously described (54). Residual cell aggregates were removed by filtration on a nylon cell strainer with 100-μm pores. C15 cell suspensions were grown in HEPES-buffered RPMI medium with 7.5% fetal calf serum on plastic coated with poly(2-hydroxyethylmethacrylate) (polyHEMA; Sigma, Saint-Quentin Fallavier, France), an antiadhesive polymer that inhibits cell attachment (60). Using this coating procedure, proliferation of murine fibroblasts was completely inhibited, whereas NPC cells grew as nonanchored spheroids or aggregates about 150 μm in diameter. Preactivated Simvastatin was solubilized in dimethylsulfoxide (DMSO; 10 mM stock solution) (Calbiochem/Merck). For biochemical experiments, C15 cells were seeded in 24-well plates at 1 million cells/well in 1.5 ml of culture medium and incubated with Simvastatin for 5 days at a final concentration of 5 μM. Control cells were incubated in culture medium with 0.05% DMSO. To provide a control for PARP cleavage, C15 cells were treated for 12 h with the CD95 agonist antibody 7C11 (250 ng/ml) (Becton-Dickinson Biosciences, Le Pont de Claix, France). For toxicity assays, NPC cells were seeded in 96-well plastic microplates coated with polyHEMA at 75,000 cells/well in 150 μl of culture medium. Cell viability was evaluated using the WST-1 assay based on a soluble form of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] according to the manufacturer’s instructions (Roche Molecular, Meylan, France). Cells were incubated with 10 μl of the WST-1 reagent added to the culture medium for 4 h at 37°C. The plates were subsequently read on an enzyme-linked immunosorbent assay reader (Dynatech MR7000) using a 450-nm filter. The mean and standard deviation were determined for quadruplicate samples.

RESULTS

Determination of optimal conditions for preparative immunoprecipitations of LMP1. We intended to identify novel proteins associated with LMP1 into lipid rafts derived from NPC cells including indirect partners and proteins whose expression was restricted to the NPC cell lineage. We chose a strategy based on preparative immunoprecipitation of LMP1-carrying complexes. Total raft complexes were isolated from C15 NPC tumor tissue by extraction in Triton lysis buffer and flotation on a density gradient. In the next step, LMP1-carrying complexes...
were captured using anti-LMP1 antibodies adsorbed on magnetic beads. This procedure was performed in experimental conditions compatible with preservation of raft lipid-protein interactions (1% Triton at 4°C in the absence of ionic detergents). During preliminary experiments OT21C was selected as the best precipitating antibody, being more efficient than S12 or OT22CN (data not shown). OT21C has been shown to bind a conformational epitope in the C-terminal intracytoplasmic region of LMP1 within residues 290 to 318 (44). Optimal ratios of antibody, magnetic beads, raft material, and reaction buffer volumes were determined in subsequent experiments. We found that it was possible to immunoprecipitate 100% LMP1 from a sample of C15 rafts corresponding to 60 µg of proteins, using 1.5 × 10^6 magnetic beads coated with 15 µg of affinity-purified OT21C, in a 600-µl reaction volume (Fig. 1). The same ratios of reagents and targets were used for subsequent preparative immunoprecipitations. In the same series of experiments, we were able to show that TRAF3 was coprecipitated with LMP1 but not the Lyn tyrosine-kinase, although it was abundant in the C15 raft fraction (Fig. 1). This was a good indication that we were able to perform selective capture of LMP1-carrying complexes from a composite mixture of membrane rafts.

**FIG. 2.** Bidirectional coimmunoprecipitation of galectin 9 and LMP1 from NPC and LCL cell extracts. (a) Coimmunoprecipitation of galectin 9 and TRAF3 with the anti-LMP1 antibody OT21C reacting on NPC and LCL rafts. Raft samples (60 µg of protein) were prepared from the C15 NPC tumor line (NPC) and two EBV-transformed B-cell lines (EBV1 and NAD+C15) and submitted to analytical immunoprecipitation using 5 µg of purified IgG covalently bound to 5 × 10^7 magnetic beads. Precipitated proteins were analyzed in two parallel blots, one stained successively with anti-LMP1 (CS1-4) and anti-galectin 9 and the other stained with anti-TRAF3 antibodies. Input, 5 µg of raft-derived proteins saved prior to the immunoprecipitation step; mIgG1, control immunoprecipitation; G28-5, CD40 immunoprecipitation performed with the G28-5 antibody (one-half of the eluted proteins); G28-5, CD40 immunoprecipitation performed with the G28-5 antibody (one-half of the eluted proteins). (b) Coimmunoprecipitation of galectin 9 with an anti-CD40 antibody reacting on whole-tumor extracts. Samples of C15 whole-tumor extracts (120 µg of protein) were submitted to immunoprecipitation using 5 µg of purified IgG coated on 5 × 10^7 magnetic beads. Precipitated proteins were analyzed in parallel Western blots stained with anti-galectin 9 (same rabbit polyclonal) and anti-LMP1 (CS1-4). Input, crude sample of C15 whole-tumor extract containing 40 µg of protein saved prior to the immunoprecipitation step; G28-5, CD40 immunoprecipitation performed with the G28-5 antibody (one-half of the eluted proteins). (c) Lack of coimmunoprecipitation of galectin 9 with an anti-CD40 antibody reacting on whole-tumor extracts. Samples of C15 whole-tumor extracts (120 µg of protein) were submitted to immunoprecipitation using 5 µg of purified IgG coated on 5 × 10^7 magnetic beads. Precipitated proteins were analyzed in parallel Western blots stained with anti-CD40 (MAb 89) and anti-galectin 9 antibodies. Protein gels prepared for CD40 detection were run in nondenaturing conditions as required for MAb 89 staining, thereby giving several bands and precluding molecular weight determination (8). Input, crude sample of C15 whole-tumor extract containing 40 µg of protein saved prior to the immunoprecipitation step; mIgG1, control immunoprecipitation; G28-5, CD40 immunoprecipitation performed with G28-5 antibody (one-half of the eluted proteins); G28-5, CD40 immunoprecipitation performed with the G28-5 antibody (one-half of the eluted proteins). (d) Coimmunoprecipitation of LMP1 with an anti-galectin 9 antibody reacting on NPC rafts and whole-tumor extracts. C15 rafts (30 µg of protein) were submitted to immunoprecipitation using 2.5 µg of purified rabbit anti-galectin 9 Ig (loaded on 20 µl of protein A beads). Whole-tumor extracts (120 µg of protein) were treated with 3.75 µg of Ig loaded on 30 µl of beads. Precipitated proteins were analyzed in parallel Western blots stained with anti-galectin 9 (same rabbit polyclonal) and anti-LMP1 (CS1-4). Input, 10 µg of raft-derived protein or 30 µg of whole-tumor extract saved prior to the immunoprecipitation step; IgG, control immunoprecipitation performed with nonspecific rabbit Ig; galectin 9, galectin 9 immunoprecipitation performed with rabbit polyclonal antibodies directed to the C-terminal carbohydrate recognition domain of human galectin 9. This experiment was performed twice in duplicate. In each case, 25% and 100% of the eluted proteins were loaded in the gel for galectin 9 and LMP1 detection, respectively.
Preparative immunoprecipitation of LMP1 and MS/MS identification of coimmunoprecipitated proteins. In the next step, we performed MS/MS analysis of the raft complexes immunoprecipitated from 180 μg of rafts using 4.5 × 10⁶ magnetic beads coated with 45 μg of OT21C antibody. Two types of negative controls were used: C15 raft complexes submitted to immunoprecipitation with nonspecific IgG1 and complexes derived from the LMP1-negative C17 tumor line treated with OT21C. In order to reduce sample complexity, precipitated proteins eluted from the beads were submitted to a short migration (1 cm) on a small PAGE gel which was cut in nine slices. Proteins extracted from each slice were submitted to nano-liquid chromatography-electrospray ionization-quadrupole time-of-flight analysis. This whole procedure was performed twice using either the C17/OT21C or the C15/IgG1 precipitates as controls. Proteins identified at least once in the C15/OT21C precipitate but not in the controls were retained as potential LMP1 partners (Table 1). TRAF3 was detected once in the OT21C precipitate whereas LMP1 itself was never detected, probably because it has only a few trypsin digestion sites (9 sites for LMP1 in contrast to 75 sites for TRAF3).

Demonstration of LMP1-galectin 9 interactions in NPC and LCL cells. Subsequent investigations were focused on galectin 9 for two main reasons: (i) this galactosyl binding protein is known to be very abundant in malignant cells of Hodgkin’s disease, which is frequently associated with EBV and has intense LMP1 expression (21, 59); (ii) another human galectin, galectin 4, has been shown to play a role in the stability of lipid rafts (4, 22). A series of investigations was performed to confirm the interactions of LMP1 with galectin 9 using immunoprecipitation and Western blotting (Fig. 2). Galectin 9 was coprecipitated from NPC and LCL rafts by OT21C and revealed by using a specific polyclonal antibody. Depending on the experiment, two to four isoforms of galectin 9 were visualized in the crude raft extract as well as in the precipitate (Fig. 2a). These isoforms are generated by alternative splicing of exons 5 and 10, and possibly by posttranslational modifications (25, 41). Coprecipitation of galectin 9 was observed for both the EBV1 and NAD+C15 LCLs which carry the B95-8 and C15 strains of EBV, respectively. Galectin 9 was also coprecipitated from NPC whole-tumor extracts not only with the OT21C antibody (directed to the LMP1 C terminus) but also with OT22CN (directed to the LMP1 N terminus) (Fig. 2b). However, there was a higher relative amount of galectin 9 coprecipitated with OT21C (about 20% instead of 10% for OT22CN). To further assess the specificity of galectin 9 coprecipitation with LMP1, another type of control experiment was done using an antibody directed to the CD40 receptor, a cellular membrane protein which like LMP1 is constitutively accumulated in membrane rafts (2, 32). As shown in Fig. 2c, no galectin 9 was coimmunoprecipitated with CD40. The LMP1-galectin 9 interaction was also documented by doing coimmunoprecipitations of LMP1 with anti-galectin 9 antibodies. These experiments were performed on NPC rafts and whole-tumor extracts (Fig. 2d). Although the LMP1 band obtained from whole-tumor extract was faint, it was consistent in several experiments. Apparently, a smaller proportion of LMP1 molecules was coprecipitated with galectin 9 from whole-tumor extract compared to membrane rafts. One possible explanation could be that LMP1 and galectin 9 molecules interact more frequently in membrane rafts than in other cell compartments. To provide additional evidence of LMP1 interactions with galectin 9 at the single-cell level, we performed immunofluorescence staining of fixed cells and confocal analysis with anti-LMP1 and galectin 9 antibodies. Partial colocalization of these two proteins was observed in C15 NPC cells (Fig. 3).

TRAF3 binding to LMP1 is not required for LMP1-galectin 9 interactions. TRAF3 is a major partner protein of LMP1. We along with others have previously shown that it is recruited by...
LMP1 from the cytosol into membrane rafts (1, 2, 24). To determine whether TRAF3-LMP1 binding is required for LMP1 interaction with galectin 9, LMP1-galectin 9 association was investigated in HeLa cells transfected with the galectin 9 gene and either wild-type B95-8 LMP1 or a mutant LMP1 deleted of the critical TRAF3-binding motif PXQXT (residues 204 to 208) (45). As shown in Fig. 4, galectin 9 was coprecipitated with wild-type or mutant LMP1 with the same efficiency, providing evidence that TRAF3 is dispensable for galectin 9-LMP1 interaction. In addition, galectin 9 was also readily coprecipitated with another mutant form of LMP1 deleted not only of the PXQXT motif but also of the YDD motif (residues 384 to 386) which is required for LMP1-TRADD binding (data not shown) (37).

FIG. 5. Cell lineage and subcellular distribution of galectin 9. (a) Constitutive expression of galectin 9 in various types of lymphoid and epithelial cells. EBV1 and NAD+ C15 are EBV-transformed B-cell lines (LCL). Ramos, BL2, and Daudi are Burkitt lymphoma cell lines. BL2-B95 was obtained by EBV conversion of BL2 cells infected with the B95-8 strain. Regarding epithelial cells, all protein extracts were prepared from xenografted tumors (C15 and C17 are permanently propagated into nude mice; other epithelial cells were specially grown as tumors into nude mice for the consistency of this analysis). For each cell type, 20 μg of whole-cell protein extract was analyzed by Western blotting. (b) Association of galectin 9 with membrane rafts in both LMP1-positive and -negative NPC cells. C15 and C17 tumor pieces were homogenized in MBS-Triton buffer, subjected to a raft flotation assay, and analyzed by Western blotting. The flotation assay generates three cell fractions in addition to the raft fraction: an LSP and an HSP, containing mostly cytoskeletal elements, and fraction F40 recovered in the 40% sucrose layer of the step gradient. F40 contains most components of the cytosol and nonraft membranes (11). Ten micrograms of protein was loaded per lane. In agreement with the data presented in panel a, galectin 9 was much more abundant in C15 than in C17 material (corresponding films were exposed 2 and 10 min, respectively). However, the ratio of galectin 9 concentration in the rafts compared to the initial extract was in the same range for the C15 (LMP1-positive) and the C17 (LMP1-negative) xenografts. (c) Galectin 9 expression in clinical specimens of NPC. NPC tissue sections from nine patients were stained with a primary anti-galectin 9 and a secondary peroxidase-labeled antibody and finally counterstained with Mayer’s hematoxylin. Galectin 9 expression by malignant cells was found in all 9 biopsies; it was very intense for seven out of nine cases. Results from two patients (patients 2 and 3) are presented in this figure. A very strong expression of galectin 9 is visible in tumor cells (T). In contrast, galectin 9 is at a low abundance in the lymphoid stroma (LS) and the adjacent nonmalignant mucosa (PM; parakeratosic mucosa). In the case of patient 3, the staining of malignant cells is predominant at the plasma membrane.
Cell and tissue distribution of galectin 9. According to previous reports, galectin 9 expression is restricted to some normal tissues and some special types of malignancies (25). To obtain more information regarding the relationship between EBV infection and galectin 9 expression, we investigated its expression in a series of lymphoid and epithelial cells. Very intense expression was recorded in EBV-positive NPC tumor lines and EBV-transformed B-cell lines (EBV1 and NAD+H11001C15) (Fig. 5a). In contrast, all Burkitt cell lines were negative for galectin 9, including one originally infected by EBV (Daudi) and one converted by in vitro EBV infection (BL2-B95) (Fig. 5a). Although it was not as high as in C15, galectin 9 expression was very high in the LMP1-negative NPC tumor lines C17 and C666-1 (Fig. 5a). For both C15 and C17, there was a preferential association of galectin 9 with membrane rafts (Fig. 5b). In contrast, no galectin 9 expression or a much weaker expression was recorded in non-NPC EBV-negative epithelial cell lines (Fig. 5b). In summary, in vitro investigations suggested that a very high level of galectin 9 expression was a specific feature of NPC and LCL cells. To confirm galectin 9 expression by NPC cells in the patients, a series of fresh NPC biopsies was analyzed by immunohistochemistry with our anti-galectin 9 antibody. Intense galectin 9 expression by malignant cells was found in seven out of nine biopsies. Two characteristic examples are displayed in Fig. 5c. Two of nine specimens had weaker galectin 9 expression levels; they were peculiar, differentiated forms of NPC from French patients. Staining on infiltrating lymphocytes was much weaker in all specimens. Adjacent normal mucosa was either completely negative or weakly stained.

LMP1 and galectin 9 accumulation into NPC cell rafts is not inhibited by Simvastatin. It has been reported by Katano et al. that Simvastatin, an HMG (3-hydroxy-3-methylglutaryl)-coenzyme A reductase inhibitor and raft-modifying agent, induced dissociation of LMP1 from lipid rafts and subsequent apoptosis of LCL cells in about 5 days (31). Therefore, it was decided to assess the impact of Simvastatin on the raft distribution of LMP1 and galectin 9 in NPC cells. First, the range of active drug concentrations was determined in vitro on cells resulting from dispersion of the C15 and C17 xenografts using an assay of cell viability and proliferation. Significant decreases in cell viability were obtained when cells were treated for 5 days with concentrations of Simvastatin as low as 2 μM. These toxic effects were similar for the LMP1-positive and -negative NPC...
cells derived from the C15 and C17 xenografts, respectively (Fig. 6a). C15 cells treated with 5 \( \mu \)M Simvastatin for 5 days were examined by electron microscopy. About 50% of treated cells displayed a morphology suggestive of necrosis (data not shown). Another subset of about 25% of cells underwent distinctive morphological changes: a general loss of cell connections, a transition to round-shaped cells and nuclei, and intense vacuolization (Fig. 6b). These alterations were reminiscent of morphological changes previously reported for pancreatic carcinoma cells treated with HMG-coenzyme A reductase inhibitors (38). In some cells, partial chromatolysis at the periphery of the nucleus was suggestive of apoptosis-like programmed cell death, also called “caspase-independent apoptosis” (40) (Fig. 6b). Simvastatin did not stimulate PARP cleavage in C15 cells, providing additional evidence that drug toxicity was not mediated by massive caspase-dependent apoptosis (Fig. 6c). In subsequent experiments, raft distributions of LMP1, galectin 9, and TRAF3 were investigated in C15 cells treated with Simvastatin for 5 days. We could see no reduction in the amount of LMP1, TRAF3, and galectin 9 contained in C15 rafts using two concentrations of Simvastatin, i.e., 2 \( \mu \)M, which did not induce maximal toxicity (data not shown), and 5 \( \mu \)M (Fig. 7a). However, we noted a modest but consistent increase in the whole-cell concentration of LMP1 and galectin 9 (Fig. 7b).

**DISCUSSION**

The development of each type of EBV-associated malignancy requires a complex interplay between a specific cellular context and a specific mode of viral expression. Even in the restricted field of EBV-associated epithelial malignancies, there are major differences between EBV-associated gastric carcinomas and NPC in terms of cell differentiation and viral gene expression (56). Therefore, it is important to investigate the status of EBV products in cells that retain, as much as possible, the characteristics of NPC cells contained in clinical specimens. Such studies have long been hampered by technical difficulties in manipulating these cells in vitro. The development of proteomic methods has opened new possibilities. By application of preparative immunoprecipitation and mass spectrometry analysis on membrane rafts derived from an NPC xenograft, we have identified galectin 9 as a novel partner of LMP1. To our knowledge, it is the first example of a membrane protein that has been shown to specifically interact with LMP1. All previously described LMP1 partners are cytosolic molecules, for example, the TRAF molecules, TRADD, BRAM1, and SCF (Skp-cullin-F box) E3 ubiquitin ligase (10, 37, 58). We have found that galectin 9 is consistently and strongly expressed in NPC cells; in most cases, it is detected in malignant cells at a much higher level than in adjacent nonmalignant mucosa. Galectin 9 was first described in Hodgkin’s disease as a tumor antigen (59). It has multiple functions including its role as a membrane urate transporter and eosinophil chemottractant (25, 41, 42). It has a restricted tissue distribution. In mice, galectin 9 is strongly expressed by postnatal thymic epithelial cells and plays a role in clonal deletion of immature T cells (62). Interestingly, both the thymus epithelium and the nasopharyngeal mucosa derive from the embryonic pharyngeal endoderm (20). Galectin 9 is also expressed by LCL cells but not Burkitt lymphoma cells. In other words, all three types of EBV-transformed cells that have spontaneous LMP1 expression—Hodgkin cells, NPC, and LCL—also contain a high amount of galectin 9. However, it is obvious that, in terms of gene expression, galectin 9 expression is somehow independent of LMP1. For example, galectin 9 is readily detected in xenografted NPCs lacking LMP1-expression like C17 and C666-1. On the other hand, it does not show up in Burkitt cells converted by EBV or transfected with the LMP1 gene. In summary, galectin 9 expression in NPC seems to reflect a special mode of nasopharyngeal epithelial cell differentiation which is exacerbated in the context of cell transformation. Previous publications have shown that another human galectin, galectin 4, is accumulated in the rafts of intestinal epithelial cells, more precisely within a raft core component that is resistant to cholesterol extraction (4, 22). The latest of these reports provides evidence that galectin 4 plays a role in the stability of these structures (4). In light of our data, galectin 9
appears as one novel example of a galectin associated with membrane rafts.

The detection of large amounts of galectin 9 in NPC cells might also benefit our understanding of host-tumor interactions. NPCs are characterized by the presence of viral antigens in a highly inflammatory context, and the mechanisms of local immune tolerance are still poorly understood (3, 61). Therefore, it is noteworthy that galectin 9, like some other galectins, can act as a negative regulator of T-cell activation (30, 53). Because of its inhibitory effects on T cells, galectin 9 might possibly contribute to viral immune escape in NPC tumors. This hypothesis is supported by some of our recent experiments, which indicate that both LMP1 and galectin 9 can be released in the extracellular medium by NPC cells.

We have previously reported that LMP1 recruits its main adaptor TRAF3 in membrane rafts to the exclusion of TRAF2, TRAF1, or TRADD (1, 2). In contrast, galectin 9 is not recruited in membrane rafts by LMP1. It appears to be a resident raft protein even in the absence of LMP1, for example, in the C17 xenograft. In addition, it seems to be much more abundant than LMP1 in membrane rafts. According to preliminary experiments, the amount of LMP1 and galectin 9 molecules for 10 μg of rafts is about 200 and 1,200 fmol, respectively. This might explain the fact that it was difficult to precipitate more than 20% of the galectin 9 contained in the cellular extract even if it was possible to precipitate almost 100% of LMP1 (Fig. 2b). Using mutant forms of LMP1 expressed in HeLa cells, we have shown that its critical TRAF3- and TRADD-binding motifs are not required for its interaction with galectin 9. So far, we do not know whether LMP1 directly binds to galectin 9 or whether this interaction is mediated by other molecules, either lipids or proteins. Previous reports have shown that the short intracytoplasmic domain and a conserved motif of the first transmembrane segment are critical for LMP1 association with membrane rafts (12, 51, 65). Our ongoing experiments are intended to determine whether the same segments of LMP1 are required for its interaction with galectin 9.

Our data regarding LMP1-galectin 9 interactions provided a good molecular basis to investigate the effects of Simvastatin on the behavior of LMP1-carrying rafts in NPC cells. Treatment of C15 cells with Simvastatin was expected to induce the dissociation of LMP1 from membrane rafts, as previously reported for LCLs by Katano et al. (31). It was not the case: the raft distribution of LMP1 and TRAF3 as well as galectin 9 was apparently not affected by this drug, despite its strong cytotoxic effect. At the same time, the whole-cell concentrations of LMP1 and galectin 9 were increased under Simvastatin. Currently, we have no explanation for this modification. In any case, the cytotoxic effect of Simvastatin against NPC cells was almost the same for C15 (LMP1-positive) and C17 (LMP1-negative) cells, providing additional evidence that LMP1 is not a critical lethal target for Simvastatin in this cell type. Interestingly, the cytotoxic effect of Simvastatin against NPC cells was obtained at low concentrations: a concentration of only 1 μM for 2 days was sufficient to induce significant growth inhibitory effects in contrast to a concentration of more than 10 μM required to achieve a significant effect on prostate carcinoma cells (67). Thus, our data suggest that Simvastatin might be beneficial in some circumstances for NPC patients. This is especially interesting since this drug has been widely used in medical practice for several years, allowing long-term monitoring of its undesirable effects.

ACKNOWLEDGMENTS

This work was supported by grants from the Ligue Nationale contre le Cancer (comité du Cher), from the Fondation de France (no. 2001004522), and from the ARC (no. 5238). C. K. was supported by a fellowship from the French Ministère de la Recherche et de la Technologie.

We thank V. Velasco for technical assistance and J. Wiels, M. Lipinski, and G. Pierrott for helpful discussions.

REFERENCES


binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. J. Virol. 77:1316–1328.


Wang, F., L. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Richardson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nucleic acids 2 and 3 are effectors of phenotypic changes.


